Dividend Assets Capital LLC raised its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 231.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 25,854 shares of the biopharmaceutical company’s stock after acquiring an additional 18,044 shares during the period. Dividend Assets Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,233,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Capital Investment Counsel Inc boosted its stake in Bristol-Myers Squibb by 3.4% in the 4th quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 200 shares during the period. James Investment Research Inc. boosted its stake in Bristol-Myers Squibb by 36.5% in the 1st quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 219 shares during the period. Squar Milner Financial Services LLC boosted its stake in Bristol-Myers Squibb by 5.6% in the 1st quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 223 shares during the period. Seizert Capital Partners LLC boosted its stake in Bristol-Myers Squibb by 3.8% in the 4th quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock worth $315,000 after purchasing an additional 224 shares during the period. Finally, Modera Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 4.3% in the 4th quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 229 shares during the period. Institutional investors own 77.58% of the company’s stock.

In related news, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the sale, the insider now directly owns 3,066 shares in the company, valued at approximately $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was purchased at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the purchase, the director now directly owns 27,000 shares in the company, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Company insiders own 0.12% of the company’s stock.

BMY has been the subject of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Bristol-Myers Squibb in a research note on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price for the company. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $53.00 to $55.00 in a research note on Friday, May 3rd. BMO Capital Markets restated a “buy” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, February 19th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Tuesday, March 5th. Finally, Bank of America reduced their price objective on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research note on Tuesday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $56.69.

Bristol-Myers Squibb stock opened at $46.12 on Tuesday. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. The stock has a market cap of $74.21 billion, a PE ratio of 11.59, a price-to-earnings-growth ratio of 2.12 and a beta of 0.74.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The company had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the business posted $0.94 EPS. The company’s quarterly revenue was up 14.0% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/06/04/dividend-assets-capital-llc-acquires-18044-shares-of-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: What are convertible shares? 

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.